Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Brant Inman: ASCO GU highlights

Brant Inman • 13 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer Antibodies BCG Enfortumab vedotin Nadofaragene firadenovec Pembrolizumab

Brant Inman, MD, MS, Duke University Medical Center, Durham, NC, discusses his personal highlights from this year’s meeting. Specifically, he mentions combining enfortumab vedotin and pembrolizumab in patients with metastatic bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Brant Inman

1:05
Heat-based therapies to treat bladder cancer
Brant Inman • 13 Feb 2020
1:10
Key bladder cancer updates from ASCO GU 2019
Brant Inman • 15 Feb 2019
2:03
Hyperthermia for the treatment of bladder cancer
Brant Inman • 15 Feb 2019
2:03
The evolution of bladder cancer treatment and the immuno-oncology era
Brant Inman • 15 Feb 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals